Article Reporting Anecdotal Success of CytoDyn’s Leronlimab (Vyrologix™) in Treatment of Critically Ill COVID-19 Patients Accepted for Journal Publication; Four Patients, Initially on Mechanical Ventilators, Fully Recover After Leronlimab Treatment

On Decembr 30, 2020, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing Vyrologix™ (leronlimab) (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that a research manuscript submitted by first author Nicholas J. Agresti, MD, has been accepted for publication in the Journal of Translational Autoimmunity. The research findings of Dr. Agresti and colleagues were based on four critically ill COVID-19 patients treated with leronlimab under an FDA-approved emergency investigational new drug (eIND) application. All four were on mechanical ventilators and fully recovered following leronlimab treatment. Dr. Agresti is a gastroenterologist in the Southeast Georgia Health System. The manuscript (Ms. No. JTAUTO-D-20-00043R1) is entitled “Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab.” The accepted research paper can be accessed here (https://d1io3yog0oux5.cloudfront.net/cytodyn/files/pages/cytodyn/db/256/content/JTAUTO-D-20-00043_R1+_3__1_.pdf). Additional authors on the paper included Bruce Patterson, MD, CEO and Founder, Incell Dx; Kabir Mody, MD, Mayo Clinic; Jacob Lalezari, MD, CytoDyn advisor, now CMO at Virion; Jonah B. Sacha, PhD, Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon; Harish Seethamraju, MD, Medical Director, Advanced Lung Failure and Lung Transplant, Montefiore Medical Center; Seth Gross, MD, NYU Langone Gastroenterology Associates; Scott Kelly, MD, CMO, CytoDyn; Nader Pourhassan, PhD, President and CEO, CytoDyn, and Kush Dody, MBBS, Vice President, Clinical Operations, Amarex Clinical Research, among others. Dr. Agresti stated:
Login Or Register To Read Full Story